Skip to main content
Omniscient Neurotechnology logo

Omniscient Neurotechnology

Sydney, New South Wales, AustraliaFounded 2019

  • Neuroimaging
  • Series D

Omniscient Neurotechnology develops digital brain-mapping technology that helps clinicians and researchers understand complex brain connectivity, or connectomics. Its platform turns neural data into insights designed to support more informed decisions in neurosurgery and neurology.

Open roles
1
Posted last 30 days
1
Raised
$137M
Jan 2026
Series D
Investors
5

reccy insights

Recent highlights

On September 11, 2026, Omniscient Neurotechnology launched Quicktome Deep Brain (DB), a workflow for patient-specific connectomic analysis in deep brain stimulation procedures. The launch was accompanied by news of the company’s third FDA clearance, extending its platform into the deep brain stimulation market. In January 2026, the company announced a new CPT code for connectomic analysis, a milestone that may support clinical adoption and reimbursement for brain-network mapping. Its Series D was announced on January 16, 2026: the structured round amount is A$20 million, equivalent to $13,366,000, with National Reconstruction Fund Corporation and OIF Ventures listed as lead investors. Earlier, in June 2024, Omniscient closed a $60 million Series C. Together, the regulatory milestone, reimbursement development, product expansion and financing indicate progress across clinical validation, commercialization and market access. The available company information does not identify specific partnership announcements, awards or executive appointment changes to add to this timeline.

Written by reccy's AI from company sites, press and funding records · updated Nov 2026

Open roles1

Hiring news

The company maintains a careers page with open positions.

What makes Omniscient Neurotechnology distinct

  1. 01Focuses on connectomics to make complex brain-network data more accessible to clinicians and researchers.
  2. 02Developed a platform for mapping human functional brain connectivity at scale.
  3. 03Combines expertise in neurosurgery, neuroscience, data science and machine learning.
  4. 04Aims to help clinicians identify underlying causes of neurological problems and inform care decisions.
  5. 05Its technology has received multiple FDA clearances.

Technology & products2

  • Quicktome

    An AI-powered connectomic analysis platform providing patient-specific brain-network insights to support clinical decision-making in neurosurgery and neurology.

  • Quicktome Deep Brain (DB)

    A cloud-based workflow using patient imaging to localize deep brain stimulation leads, segment deep brain structures and map connecting white-matter tracts.

  • Quicktome, an AI-powered platform for connectomic analysis.
  • Quicktome Deep Brain (DB), a workflow for deep brain stimulation procedures.
  • Digital brain maps for analyzing brain connectivity.
  • AI and cloud-based analysis of complex neural data.
  • Methods for localizing stimulation leads, segmenting deep brain structures and mapping white-matter tracts.

Recent updates2

  • Sep 11, 2026Product launch

    Omniscient launched Quicktome Deep Brain (DB), a workflow within its Quicktome platform for patient-specific connectomic analysis supporting deep brain stimulation procedures.

    biospace.com
  • Jul 24, 2025Partnership

    Omniscient and The Jacobs Institute, Inc. Announce Strategic Partnership to Pioneer Clinical Connectomics

    globenewswire.com

In the Cortex

Funding

$137M disclosed
  • Series DJan 2026
    $13.4MLed by National Reconstruction Fund Corporation, OIF Ventures
  • Series CJun 2024
    $60MLed by Gina Rinehart, Will Vicars
  • Series BJul 2021
    $29.9MLed by Will Vicars
Latest valuation $295 million5 investors

Similar companies

About Omniscient Neurotechnology

Products
Quicktome, Quicktome Deep Brain (DB)
Leadership
Michael Sughrue, Chief Medical Officer & DirectorStephane Doyen, Chief Data Scientist & DirectorRob Malcolm, COOTodd Smalley, Chief Commercial Officer
Focus areas
Digital health, neurotechnology, connectomics, brain mapping, neurology, neurosurgery, AI/ML, clinical software
Headquarters
Sydney, New South Wales, Australia
Founded
2019
Employees
51–100
Patents granted
71
Trademarks
19